Terms: = Leukemia AND TAL1, TCL5, 6886, ENSG00000162367, SCL, P17542, tal-1
590 results:
1. The role of quiescent thymic progenitors in TAL/LMO2-induced T-ALL chemotolerance.
O'Connor KW; Kishimoto K; Kuzma IO; Wagner KP; Selway JS; Roderick JE; Karna KK; Gallagher KM; Hu K; Liu H; Li R; Brehm MA; Zhu LJ; Curtis DJ; Tremblay CS; Kelliher MA
Leukemia; 2024 May; 38(5):951-962. PubMed ID: 38553571
[TBL] [Abstract] [Full Text] [Related]
2. Integrated analysis of transcriptome and genome variations in pediatric T cell acute lymphoblastic leukemia: data from north Indian tertiary care center.
Singh M; Sharma P; Bhatia P; Trehan A; Thakur R; Sreedharanunni S
BMC Cancer; 2024 Mar; 24(1):325. PubMed ID: 38459434
[TBL] [Abstract] [Full Text] [Related]
3. Pathogenic GATA2 genetic variants utilize an obligate enhancer mechanism to distort a multilineage differentiation program.
Katsumura KR; Liu P; Kim JA; Mehta C; Bresnick EH
Proc Natl Acad Sci U S A; 2024 Mar; 121(10):e2317147121. PubMed ID: 38422019
[TBL] [Abstract] [Full Text] [Related]
4. Williams-Beuren syndrome in pediatric T-cell acute lymphoblastic leukemia: A rare case report and review of literature.
Yang R; Ai Y; Bai T; Lu XX; He G
Medicine (Baltimore); 2024 Feb; 103(7):e36976. PubMed ID: 38363891
[TBL] [Abstract] [Full Text] [Related]
5. Suppression of super-enhancer-driven tal1 expression by KLF4 in T-cell acute lymphoblastic leukemia.
Noura M; Matsuo H; Yasuda T; Tsuzuki S; Kiyoi H; Hayakawa F
Oncogene; 2024 Feb; 43(6):447-456. PubMed ID: 38102337
[TBL] [Abstract] [Full Text] [Related]
6. Regulatory mechanisms and context-dependent roles of tal1 in T-cell acute lymphoblastic leukemia.
Ong JZL; Tan TK; Wang L; Tan SH; Sanda T
Haematologica; 2024 May; 109(5):1359-1372. PubMed ID: 37855064
[TBL] [Abstract] [Full Text] [Related]
7. Inhibition of the NOTCH and mTOR pathways by nelfinavir as a novel treatment for T cell acute lymphoblastic leukemia.
Chang YS; Gills JJ; Kawabata S; Onozawa M; Della Gatta G; Ferrando AA; Aplan PD; Dennis PA
Int J Oncol; 2023 Nov; 63(5):. PubMed ID: 37800623
[TBL] [Abstract] [Full Text] [Related]
8. Characteristics and therapeutic approaches for patients diagnosed with T-ALL/LBL exhibiting t(8;14)(q24;q11)/TCRA/D:MYC translocation.
Zhang X; Wang T; Zhang Y; Wang F; Chen J; Ni J; Sun R; Wei Z; Zhang G; Li W; Li J; Lu P
Leuk Lymphoma; 2023 Dec; 64(13):2133-2139. PubMed ID: 37674391
[TBL] [Abstract] [Full Text] [Related]
9. tal1 hijacks MYCN enhancer that induces MYCN expression and dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia.
Tan SH; Tan TK; Yokomori R; Liao M; Huang XZ; Yeoh AEJ; Sanda T
Leukemia; 2023 Oct; 37(10):1969-1981. PubMed ID: 37591943
[TBL] [Abstract] [Full Text] [Related]
10. S1P-S1PR3-RAS promotes the progression of S1PR3
Zhu D; Jiang T; Ma D; Zhang H; Zhang J; Lv W; Gong M; Wang H; Liu Z; Su H; Zeng L; Liu S; Tang S; Yang B; Tshavuka FI; Fu G; Liu Z; Peng D; Liu H; Yan Z; Cao Z; Zhao H; He TC; Yu J; Shu Y; Zou L
Leukemia; 2023 Oct; 37(10):1982-1993. PubMed ID: 37591940
[TBL] [Abstract] [Full Text] [Related]
11. The Clinicogenomic Landscape of Induction Failure in Childhood and Young Adult T-Cell Acute Lymphoblastic leukemia.
O'Connor D; Demeulemeester J; Conde L; Kirkwood A; Fung K; Papaleonidopoulou F; Bloye G; Farah N; Rahman S; Hancock J; Bateman C; Inglott S; Mee J; Herrero J; Van Loo P; Moorman AV; Vora A; Mansour MR
J Clin Oncol; 2023 Jul; 41(19):3545-3556. PubMed ID: 37098241
[TBL] [Abstract] [Full Text] [Related]
12. [Clinical features of 19 patients with SIL-tal1-positive T-cell acute lymphoblastic leukemia].
Wang LJ; Chen Y; Xiang M; Yang XF; Chen SN
Zhonghua Xue Ye Xue Za Zhi; 2023 Feb; 44(2):132-136. PubMed ID: 36948867
[No Abstract] [Full Text] [Related]
13. A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia.
Krishnan V; Schmidt F; Nawaz Z; Venkatesh PN; Lee KL; Ren X; Chan ZE; Yu M; Makheja M; Rayan NA; Lim MGL; Cheung AMS; Bari S; Chng WJ; Than H; Ouyang J; Rackham O; Tan TZ; Hwang WYK; Chuah C; Prabhakar S; Ong ST
Blood; 2023 Jun; 141(22):2738-2755. PubMed ID: 36857629
[TBL] [Abstract] [Full Text] [Related]
14. Harnessing the MYB-dependent tal1 5'super-enhancer for targeted therapy in T-ALL.
Smith C; Touzart A; Simonin M; Tran-Quang C; Hypolite G; Latiri M; Andrieu GP; Balducci E; Dourthe MÉ; Goyal A; Huguet F; Petit A; Ifrah N; Baruchel A; Dombret H; Macintyre E; Plass C; Ghysdael J; Boissel N; Asnafi V
Mol Cancer; 2023 Jan; 22(1):12. PubMed ID: 36650499
[TBL] [Abstract] [Full Text] [Related]
15. Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia.
Aiba M; Shigematsu A; Suzuki T; Miyagishima T
Ann Hematol; 2023 Mar; 102(3):541-546. PubMed ID: 36646889
[TBL] [Abstract] [Full Text] [Related]
16. tal1 activation in T-cell acute lymphoblastic leukemia: a novel oncogenic 3' neo-enhancer.
Smith C; Goyal A; Weichenhan D; Allemand E; Mayakonda A; Toprak U; Riedel A; Balducci E; Manojkumar M; Pejkovska A; Mücke O; Sollier E; Bakr A; Breuer K; Lutsik P; Hermine O; Spicuglia S; Asnafi V; Plass C; Touzart A
Haematologica; 2023 May; 108(5):1259-1271. PubMed ID: 36632736
[TBL] [Abstract] [Full Text] [Related]
17. The trace that is valuable: serum copper and copper to zinc ratio for survival prediction in younger patients with newly diagnosed acute myeloid leukaemia.
Li T; Shi L; Wei W; Xu J; Liu Q
BMC Cancer; 2023 Jan; 23(1):14. PubMed ID: 36604732
[TBL] [Abstract] [Full Text] [Related]
18. [Detection of Fusion Gene and Prognosis Analysis in Children with Acute Lymphoblastic leukemia of Different Immunophenotypes].
Liu CY; Pan YS; Yang H; Hu X; Chen HY; Liu WJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1673-1678. PubMed ID: 36476888
[TBL] [Abstract] [Full Text] [Related]
19. Mapping the genetic features of T-ALL cases through simplified NGS approach.
García-Aznar JM; Alonso S; Iglesias DU; de Ugarriza PL; López CÁ; Balbín M; Del Castillo TB
Clin Immunol; 2022 Dec; 245():109151. PubMed ID: 36270471
[TBL] [Abstract] [Full Text] [Related]
20. Targeting dual oncogenic machineries driven by tal1 and PI3K-AKT pathways in T-cell acute lymphoblastic leukemia.
Lim FQ; Chan AS; Yokomori R; Huang XZ; Theardy MS; Yeoh AEJ; Tan SH; Sanda T
Haematologica; 2023 Feb; 108(2):367-381. PubMed ID: 36073513
[TBL] [Abstract] [Full Text] [Related]
[Next]
